Stintzing S, Wirapati P, Lenz HJ, Neureiter D, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol 2019;30:1796-1803.
PMID: 31987086